Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Relatlimab is a...
7 KB (312 words) - 06:00, 3 January 2024
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed...
13 KB (761 words) - 04:27, 31 March 2024
Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune...
38 KB (4,316 words) - 10:24, 26 August 2024
In the same year, the FDA approved a combination therapy consisting of relatlimab and nivolumab for the treatment of some cases of advanced melanoma. In...
47 KB (4,870 words) - 06:39, 18 September 2024
complications from graft-versus-host disease. The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March...
154 KB (16,091 words) - 19:34, 29 August 2024
spike protein receptor binding domain (RBD) of SARS-CoV-2 Y COVID-19 Relatlimab mab human LAG3 melanoma Remtolumab mab human IL-17A, TNF Reslizumab Cinqair...
136 KB (4,020 words) - 06:13, 27 September 2024
Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune...
2 KB (87 words) - 01:28, 30 May 2023
Talquetamab L01FY01 Pertuzumab and trastuzumab L01FY02 Nivolumab and relatlimab L01FY03 Prolgolimab and nurulimab L01XA01 Cisplatin L01XA02 Carboplatin...
12 KB (877 words) - 15:36, 25 January 2024
which take the brakes off the anti-cancer immune response. An example is relatlimab, an anti-LAG3 monoclonal antibody that is currently in phase 2 clinical...
52 KB (6,646 words) - 14:14, 26 July 2024
clinical trial, RELATIVITY-047, evaluating the efficacy of anti-LAG3 (Relatlimab) in combination with anti-PD1 (Nivolumab) in patients with metastatic...
30 KB (3,517 words) - 08:24, 3 July 2024